These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 24142110)
1. Key intestinal genes involved in lipoprotein metabolism are downregulated in dyslipidemic men with insulin resistance. Couture P; Tremblay AJ; Kelly I; Lemelin V; Droit A; Lamarche B J Lipid Res; 2014 Jan; 55(1):128-37. PubMed ID: 24142110 [TBL] [Abstract][Full Text] [Related]
2. Differential associations between plasma concentrations of insulin and glucose and intestinal expression of key genes involved in chylomicron metabolism. Drouin-Chartier JP; Tremblay AJ; Lemelin V; Lamarche B; Couture P Am J Physiol Gastrointest Liver Physiol; 2018 Aug; 315(2):G177-G184. PubMed ID: 29698057 [TBL] [Abstract][Full Text] [Related]
3. Substitution of dietary ω-6 polyunsaturated fatty acids for saturated fatty acids decreases LDL apolipoprotein B-100 production rate in men with dyslipidemia associated with insulin resistance: a randomized controlled trial. Drouin-Chartier JP; Tremblay AJ; Lépine MC; Lemelin V; Lamarche B; Couture P Am J Clin Nutr; 2018 Jan; 107(1):26-34. PubMed ID: 29381796 [TBL] [Abstract][Full Text] [Related]
4. Dietary medium-chain triglyceride supplementation has no effect on apolipoprotein B-48 and apolipoprotein B-100 kinetics in insulin-resistant men. Tremblay AJ; Lamarche B; Labonté MÈ; Lépine MC; Lemelin V; Couture P Am J Clin Nutr; 2014 Jan; 99(1):54-61. PubMed ID: 24172309 [TBL] [Abstract][Full Text] [Related]
5. C-reactive protein levels are inversely correlated with the apolipoprotein B-48-containing triglyceride-rich lipoprotein production rate in insulin resistant men. Drouin-Chartier JP; Tremblay AJ; Hogue JC; Leclerc M; Labonté MÈ; Marin J; Lamarche B; Couture P Metabolism; 2017 Mar; 68():163-172. PubMed ID: 28183448 [TBL] [Abstract][Full Text] [Related]
6. Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance. Drouin-Chartier JP; Tremblay AJ; Hogue JC; Lemelin V; Lamarche B; Couture P J Lipid Res; 2018 Aug; 59(8):1501-1509. PubMed ID: 29946054 [TBL] [Abstract][Full Text] [Related]
7. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. Hogue JC; Lamarche B; Tremblay AJ; Bergeron J; Gagné C; Couture P J Lipid Res; 2007 Jun; 48(6):1336-42. PubMed ID: 17337758 [TBL] [Abstract][Full Text] [Related]
8. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Duez H; Lamarche B; Valéro R; Pavlic M; Proctor S; Xiao C; Szeto L; Patterson BW; Lewis GF Circulation; 2008 May; 117(18):2369-76. PubMed ID: 18443237 [TBL] [Abstract][Full Text] [Related]
9. Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production. Duez H; Lamarche B; Uffelman KD; Valéro R; Szeto L; Lemieux S; Cohn JS; Lewis GF J Clin Endocrinol Metab; 2008 May; 93(5):1722-9. PubMed ID: 18285418 [TBL] [Abstract][Full Text] [Related]
10. Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism in obese, nondiabetic humans. Padilla N; Maraninchi M; Béliard S; Berthet B; Nogueira JP; Wolff E; Nicolay A; Bégu A; Dubois N; Grangeot R; Mattei C; Vialettes B; Xiao C; Lewis GF; Valéro R Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2330-7. PubMed ID: 25104797 [TBL] [Abstract][Full Text] [Related]
11. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Federico LM; Naples M; Taylor D; Adeli K Diabetes; 2006 May; 55(5):1316-26. PubMed ID: 16644688 [TBL] [Abstract][Full Text] [Related]
12. Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes. Nogueira JP; Maraninchi M; Béliard S; Padilla N; Duvillard L; Mancini J; Nicolay A; Xiao C; Vialettes B; Lewis GF; Valéro R Arterioscler Thromb Vasc Biol; 2012 Apr; 32(4):1039-44. PubMed ID: 22308041 [TBL] [Abstract][Full Text] [Related]
13. n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich Lipoprotein Kinetics in Men with Type 2 Diabetes. Tremblay AJ; Lamarche B; Hogue JC; Couture P J Diabetes Res; 2016; 2016():2909210. PubMed ID: 27034958 [TBL] [Abstract][Full Text] [Related]
14. Associations between insulin-like growth factor binding protein-2 and lipoprotein kinetics in men. Rauzier C; Lamarche B; Tremblay AJ; Couture P; Picard F J Lipid Res; 2022 Oct; 63(10):100269. PubMed ID: 36030928 [TBL] [Abstract][Full Text] [Related]
15. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Duez H; Lamarche B; Uffelman KD; Valero R; Cohn JS; Lewis GF Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1357-63. PubMed ID: 16614317 [TBL] [Abstract][Full Text] [Related]
16. New and emerging regulators of intestinal lipoprotein secretion. Xiao C; Dash S; Morgantini C; Lewis GF Atherosclerosis; 2014 Apr; 233(2):608-615. PubMed ID: 24534456 [TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-2 regulates release of chylomicrons from the intestine. Dash S; Xiao C; Morgantini C; Connelly PW; Patterson BW; Lewis GF Gastroenterology; 2014 Dec; 147(6):1275-1284.e4. PubMed ID: 25173752 [TBL] [Abstract][Full Text] [Related]
18. Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism. Dash S; Xiao C; Lewis GF Curr Opin Lipidol; 2016 Feb; 27(1):14-8. PubMed ID: 26628436 [TBL] [Abstract][Full Text] [Related]
19. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Chan DC; Watts GF; Ng TW; Uchida Y; Sakai N; Yamashita S; Barrett PH Clin Chem; 2005 Mar; 51(3):578-85. PubMed ID: 15650029 [TBL] [Abstract][Full Text] [Related]
20. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Dash S; Xiao C; Morgantini C; Szeto L; Lewis GF Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2895-901. PubMed ID: 24072699 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]